EUVIMEDEUVIMED entdecken
Crossref

Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription

Patrick G Schweickert iD, Dana Piovesan, Casey G Mitchell, Bryan Zepeda-Carranza, Wandi S Zhu, Alejandra Y Lopez Espinoza, Lauren Rocha, Jaskirat Singh, Martin Ian P Malgapo, Cesar Meleza, Kyle R Northington, Rebecca D Ray und 4 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Patrick G Schweickert und 15 weiteren Autor:innen. Beteiligte Einrichtung: Arcus Biosciences Inc, Hayward, California, USA. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Transcription, Genetic, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 89 Literaturangaben. Gefördert von: Arcus Biosciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Hypoxia‐inducible factor 2α (HIF‐2α) is a transcription factor that mediates the expression of genes critical for cell adaptation and survival in low oxygen (hypoxic) conditions. In cancer, hypoxic conditions or molecular alterations within cancer cells can lead to HIF‐2α accumulation and promote tumour growth and progression. Inactivating mutations in the von Hippel–Lindau ( VHL ) gene disable the oxygen‐dependent HIF‐2α degradation pathway and cause constitutive HIF‐2α activity. VHL mutations are prevalent in clear cell renal cell carcinoma (ccRCC) where HIF‐2α is a known tumourigenic driver. HIF‐2α inhibition was shown to improve ccRCC patient outcomes clinically, warranting development of next‐generation inhibitors. Experimental Approach Pharmacological effects of a novel small molecule allosteric inhibitor of HIF‐2α, AB521 (casdatifan), were evaluated using in vitro cell‐based assays and in vivo mouse models. Key Results AB521 inhibited HIF‐2α‐mediated transcription in cancer cells, endothelial cells, and M2‐polarised macrophages. AB521 was selective for HIF‐2α, displaying no activity against HIF‐1α, and did not exhibit off‐target cytotoxicity. When delivered orally to mice, AB521 caused dose‐dependent decreases in HIF‐2α‐associated pharmacodynamic markers and significant regression of human ccRCC xenograft tumours. AB521 combined favourably with cabozantinib, a standard of care tyrosine kinase inhibitor, or zimberelimab, a clinical‐stage anti‐PD‐1 antibody, in ccRCC xenograft studies. Conclusions and Implications AB521 is a potent, selective and orally bioavailable HIF‐2α inhibitor, with favourable pharmacological properties, that is being explored clinically for the treatment of ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basic Helix-Loop-Helix ProteinsTranscription, GeneticAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorAllosteric RegulationCarcinoma, Renal CellMice, NudeKidney NeoplasmsXenograft Model Antitumor AssaysFemaleEndothelial PAS Domain-Containing Protein 1

Stichwörter der Autor:innen

AB521HIF‐2αVHL mutationcasdatifanclear cell renal cell carcinomarenal cancersmall molecule inhibitor

Substanzen

Basic Helix-Loop-Helix ProteinsAntineoplastic AgentsEndothelial PAS Domain-Containing Protein 1

Autor:innen und Institutionen

  • Arcus Biosciences Inc, Hayward, California, USA.

ORCID-Profile: Patrick G Schweickert

Förderung

  • Arcus Biosciences, Inc.

Zitieren

APA

Schweickert, P. G., Piovesan, D., Mitchell, C. G., Zepeda-Carranza, B., Zhu, W. S., Lopez Espinoza, A. Y., Rocha, L., Singh, J., Malgapo, M. I. P., Meleza, C., Northington, K. R., Ray, R. D., Zhao, X., Lawson, K. V., Walters, M. J., & Sivick, K. E. (2025). Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription. British Journal of Pharmacology. https://doi.org/10.1111/bph.70075

Vancouver

Schweickert PG, Piovesan D, Mitchell CG, Zepeda-Carranza B, Zhu WS, Lopez Espinoza AY, et al. Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription. British Journal of Pharmacology. 2025. doi:10.1111/bph.70075

BibTeX
@article{Schweickert2025,
  author = {Schweickert, Patrick G and Piovesan, Dana and Mitchell, Casey G and Zepeda-Carranza, Bryan and Zhu, Wandi S and Lopez Espinoza, Alejandra Y and Rocha, Lauren and Singh, Jaskirat and Malgapo, Martin Ian P and Meleza, Cesar and Northington, Kyle R and Ray, Rebecca D and Zhao, Xiaoning and Lawson, Kenneth V and Walters, Matthew J and Sivick, Kelsey E},
  title = {Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70075}
}
Kostenlos starten →